INFINITY PHARMACEUTICALS, INC.: Nasdaq/NYSE listing notice — Infinity Pharma receives Nasdaq delisting notice for bid price below $1.00

INFINITY PHARMACEUTICALS, INC.

Nasdaq letter received Dec 28, 2022; common stock bid price under $1.00 for 30 consecutive days.
Company has 180 calendar days, until June 26, 2023, to regain compliance.
Compliance requires closing bid price of $1.00+ for 10 consecutive business days.
If not cured, may transfer to Nasdaq Capital Market for an additional 180-day period.
Management will monitor bid price and evaluate options to regain compliance.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

INFINITY PHARMACEUTICALS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

December 28, 2022, Infinity Pharmaceuticals, Inc. (the “Company”) received a deficiency letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock (the “Common Stock”) had closed below $1.00 per share, which is the minimum bid price required to maintain continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Requirement”). The Notice has no immediate effect on the

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001140361-22-047653

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.